↓ Skip to main content

Drug adherence and multidisciplinary care in patients with multiple sclerosis: Protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated…

Overview of attention for article published in BMC Neurology, March 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
100 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Drug adherence and multidisciplinary care in patients with multiple sclerosis: Protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study)
Published in
BMC Neurology, March 2011
DOI 10.1186/1471-2377-11-40
Pubmed ID
Authors

Peter J Jongen, Gerald Hengstman, Raymond Hupperts, Hans Schrijver, Job Gilhuis, Joseph H Vliegen, Erwin Hoogervorst, Marc van Huizen, Eric van Munster, Johnny Samijn, Els de Schryver, Theodora Siepman, Martijn Tonk, Eveline Zandbergen, Jacques ten Holter, Ruud van der Kruijk, George Borm

Abstract

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system, for which no definitive treatment is available. Most patients start with a relapsing-remitting course (RRMS). Disease-modifying drugs (DMDs) reduce relapses and disability progression. First line DMDs include glatiramer acetate (GA), interferon-beta (INFb)-1a and INFb-1b, which are all administered via injections. Effectiveness of DMD treatment depends on adequate adherence, meaning year-long continuation of injections with a minimum of missed doses. In real-life practice DMD-treated patients miss 30% of doses. The 6-month discontinuation rate is up to 27% and most patients who discontinue do so in the first 12 months.Treatment adherence is influenced by the socio-economic situation, health care and caregivers, disease, treatment and patient characteristics. Only a few studies have dealt with adherence-related factors in DMD-treated patients. Self-efficacy expectations were found to be related to GA adherence. Patient education and optimal support improve adherence in general. Knowledge of the aspects of care that significantly relate to adherence could lead to adherence-improving measures. Moreover, identification of patients at risk of inadequate adherence could lead to more efficient care.In the near future new drugs will become available for RRMS. Detailed knowledge on factors prognostic of adherence and on care aspects that are associated with adequate adherence will improve the chances of these drugs becoming effective treatments. We investigate in RRMS patients the relationship between drug adherence and multidisciplinary care, as well as factors associated with adherence. Given the differences in the frequency of administration and in the side effects between the DMDs we decided to study patients treated with the same DMD, GA.

Mendeley readers

The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 2 2%
Brazil 1 1%
Spain 1 1%
Unknown 96 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 20 20%
Student > Master 19 19%
Student > Ph. D. Student 17 17%
Student > Bachelor 9 9%
Student > Doctoral Student 9 9%
Other 26 26%
Readers by discipline Count As %
Medicine and Dentistry 34 34%
Psychology 15 15%
Unspecified 12 12%
Nursing and Health Professions 10 10%
Social Sciences 7 7%
Other 22 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2015.
All research outputs
#2,506,496
of 9,394,747 outputs
Outputs from BMC Neurology
#371
of 1,306 outputs
Outputs of similar age
#50,050
of 182,228 outputs
Outputs of similar age from BMC Neurology
#12
of 61 outputs
Altmetric has tracked 9,394,747 research outputs across all sources so far. This one has received more attention than most of these and is in the 59th percentile.
So far Altmetric has tracked 1,306 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 182,228 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.